A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Exclusion Criteria

• •Presence of any symptoms of allergic rhinitis within 1 year except scattering season of cedar pollen or cypress pollen
• •Subjects who have persistent symptom caused by allergen exposure in EEC at screening period until Day 1 (pre-dose)
• •Underwent nasal surgery (include laser surgery) to improve nasal symptoms within 2 years
• •Underwent specific immunotherapy or non-specific immunotherapy within 5 years
• •Underwent medication of anti-histamine, oral mast cell stabilizer, leukotriene receptor antagonist, prostaglandin D2/thromboxane A2 receptor antagonist, Th2 cytokine inhibitor, corticosteroid (oral form, intra-nasal form, ocular form), or vasoconstrictor within 4 weeks
• •Underwent medication of corticosteroid (injection form) or anti-IgE antibody within 6 months
• •Subject who is concerned about exacerbation of the physical condition due to allergen exposure in EEC